Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
This transaction fundamentally strengthens Scinai's CDMO platform
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
Subscribe To Our Newsletter & Stay Updated